FDA, Allergan warn of foreign Botox in counterfeit packaging sold to U.S. docs

Eric Palmer A new wrinkle has developed in the fight by the FDA against counterfeit drugs. An unapproved, foreign version of the cosmetic treatment Botox has shown up in the U.S., ...

Hooters or Nobu, Novartis doc-dinners are kickbacks, feds say

Tracy Staton It's not often that the U.S. Justice Department delivers a one-two punch against a Big Pharma company. And it isn't often that prosecutors get to use the word ...

Bayer bolsters birth-control business with $1.1B Conceptus buyout

Tracy Staton What's a birth-control drug maker to do when its pills start to flag? Turn to a device instead. That's the strategy Bayer is using to bolster its contraceptives ...

AstraZeneca pitches in to develop NHS social-media app

Tracy Staton The U.K.'s struggling AstraZeneca ($ AZN) is not only looking to media that is social to develop some kind of relationship with patients; it has gone local as well. ...

FDA rejects two of the four drugs in Gilead’s blockbuster HIV drug Stribild

John Carroll The FDA has handed back a pair of new drug applications from Gilead ($ GILD) covering key products used in its blockbuster four-in-one HIV-fighting therapy Stribild. ...

On verge of $13B merger, Valeant and Actavis stop talking

Tracy Staton Valeant Pharmaceuticals was on the verge of its biggest deal yet last week. Until merger talks with generics giant Actavis fell apart, that is. The Financial Times reports ...

GlaxoSmithKline throws in the towel on $186M Parkinson’s pact with Impax

John Carroll A little more than two years after signing up GlaxoSmithKline as its Big Pharma partner on an extended-release version of a carbidopa-levodopa combo for Parkinson's ...

Jury hits Takeda with $6.5M judgment in first Actos liability case

Tracy Staton Score one for the plaintiffs in Takeda Pharmaceuticals’ Actos litigation. A California jury weighed in against the drugmaker, deciding that Takeda didn’t do ...

U.K. union makes its case against AstraZeneca’s R&D relocation

John Carroll AZ CEO Pascal Soriot Union leaders in the U.K. are fighting a rear-guard action against AstraZeneca’s ($ AZN) planned R&D relocation from Alderley Park ...

Giants team on diabetes as Merck partners with Pfizer on SGLT2 combo

John Carroll Jockeying for a leading position in the high-stakes race to develop a new generation of blockbuster diabetes drugs, Merck ($ MRK) is hitching a ride with Pfizer’s ...

Celgene taps biotech Forma for drugs in hot field of protein homeostasis

Ryan McBride Forma Therapeutics has locked in another biopharma partner. The biotech giant Celgene ($ CELG) and Forma have agreed to a broad collaboration in the field of protein ...

MedImmune chief taps top prospects, hunts new biologics deals

John Carroll   Last year AstraZeneca's MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. This year, MedImmune chief Bahija Jallal tells ...
Page 2 of 1712345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS